News from 4d pharma plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 17, 2020, 03:00 ET 4D Pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on the previously...


Jan 06, 2020, 02:00 ET Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the opening of a clinical study...


Nov 06, 2019, 02:00 ET 4D pharma plc: Preliminary Safety and Clinical Observations From Its Phase I/II Study of MRx0518 in Combination With KEYTRUDA®

4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live Biotherapeutics, today announced preliminary...


Oct 08, 2019, 02:00 ET 4D Pharma Collaborates With MSD to Develop Live Biotherapeutics for Vaccines

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces that the Company has entered...


Sep 23, 2019, 02:00 ET 4D pharma plc: Publication of Data on Neurodegenerative Disease Programmes

4D pharma plc (the "Company" or "4D") (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the...


Jul 25, 2019, 07:00 ET 4D pharma plc: Oncology Programmes Update

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on its oncology...


Jul 08, 2019, 07:00 ET 4D pharma plc Commences Phase I/II Asthma Trial

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on its lead Live...


Jun 03, 2019, 02:05 ET 4D Presents MRx0518 Combination Study at ASCO 2019, Chicago, USA

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the presentation of a poster...


May 16, 2019, 02:00 ET 4D Presents Phase Ib Clinical Data on Thetanix®

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of Live Biotherapeutics, today announced that data from the completed ...


May 13, 2019, 03:00 ET 4D Announces Participation in Neuro4D Conference, Frankfurt, Germany

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces its participation in the Neuro4D ...


Apr 29, 2019, 02:00 ET 4D Pharma Clinical Update - MRx0518 Oncology Programmes

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on the clinical...


Jan 29, 2019, 02:00 ET 4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the publication of a paper...


Jan 08, 2019, 02:10 ET 4D pharma plc: Appointment of Independent Non-Executive Directors

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the appointment of Ed...


Jan 07, 2019, 02:10 ET 4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours

4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live...


Jun 27, 2018, 12:16 ET 4D presente en IHMC 2018

4D pharma plc (AIM: DDDD), una empresa farmacéutica líder en el desarrollo de bioterapias vivas, anunció hoy que el responsable científico de la...


Jun 27, 2018, 02:00 ET Présentation de 4D pharma au congrès IHMC 2018

4D pharma plc (AIM : DDDD), une société pharmaceutique à la tête du développement de produits biothérapeutiques vivants, a annoncé aujourd'hui que le ...


Jun 27, 2018, 02:00 ET 4D Presents at IHMC 2018

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announced that the Company's Chief...


Jun 27, 2018, 02:00 ET 4D bei IHMC 2018 mit Präsentation vertreten

4D pharma plc (AIM: DDDD), ein biopharmazeutisches Unternehmen und Vorreiter bei der Entwicklung von lebenden Biotherapeutika, gibt heute bekannt,...


Jun 07, 2018, 06:49 ET 4D pharma plc llega a un acuerdo de colaboración clínica con MSD

4D pharma plc llega a un acuerdo de colaboración clínica con MSD para investigar la combinación de KEYTRUDA® (pembrolizumab) y MRx0518 en pacientes...


Jun 07, 2018, 02:00 ET 4D pharma plc: Abschluss einer klinischen Kooperationsvereinbarung mit MSD zur Untersuchung der Kombination von KEYTRUDA® (Pembrolizumab) und MRx0518 bei Patienten mit soliden Tumoren

4D pharma plc (AIM: DDDD) gab heute eine Vereinbarung mit einer Tochtergesellschaft von MSD (Handelsname von Merck & Co., Inc., Kenilworth, N.J.,...


Jun 07, 2018, 02:00 ET 4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours

4D pharma plc (AIM: DDDD) today announced an agreement with a subsidiary of MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA) to conduct a...


Jun 07, 2018, 02:00 ET Collaboration clinique entre 4D pharma plc et MSD pour étudier l'association du KEYTRUDA® (pembrolizumab) au MRx0518 chez les patients présentant des tumeurs solides

4D pharma plc (AIM: DDDD) a annoncé aujourd'hui un accord avec une filiale de MSD (nom commercial de Merck & Co., Inc., Kenilworth, New Jersey,...